iShares Self-Driving EV and Tech vs Illumina, Inc. — how do they compare? iShares Self-Driving EV and Tech trades at $33.26 (market cap $264.50M), while Illumina, Inc. trades at $275.85 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 151× iShares Self-Driving EV and Tech's market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Illumina, Inc. for 83 Days on average.
| IDRV | ILMN | |
|---|---|---|
Market Cap | $264.50M | $39.95B |
Volume | 48,021 | 3,169,503 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $293.69 |
52-Week Low | $32.68 | $91.00 |
Typical Hold Time | 73 Days | 83 Days |
Enterprise Value | — | $41.31B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Trailing returns across standard periods
Latest headlines on both assets
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →